Neuren is significant undervalued ..
Neuren Pharma ( NEU.AX)
Marketcap: only 48 million A$
Price: 0,34 A$
Awesome Pipeline :
Glypromate MCI in CABG Phase 3 ongoing
NNZ-2566 Severe TBI (traumatic brain injury) Phase 2a (deal with US Army)
NNZ-2566 Mild/Mod TBI Phase 2
Motiva Post-stroke-Apathy Phase 2b
Taylor Collison
http://preset.sphilo.com/neuren/images/NEU%200708%20-%20Hamilton.pdf
By the end 1Q CY08, we expect Neuren to be running four major
efficacy trials; namely three Phase 2 trials for NNZ-2566 in
mild/moderate and severe TBI and Motiva™ in post stroke abulia/
depression coupled with the current Phase 3 trial for Glypromate® in
CABG. All indications potentially provide Neuren with first to market,
billion dollar opportunities. With a current market cap of $40.2m, Neuren
remains a solid value proposition in the sector, where FDA INDs for mid
to late stage clinical trials continues to remain a vexing proposition. We
maintain our Speculative Buy recommendation and price target of $1.30,
though expect to make changes to our valuation model once the
acquisition has closed, which we expect during the current Q.
- Forums
- ASX - By Stock
- CT1
- cheapest biotech stock on asx
cheapest biotech stock on asx
Featured News
Add CT1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.949M |
Open | High | Low | Value | Volume |
0.2¢ | 0.2¢ | 0.2¢ | $109 | 54.44K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 7443517 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 6778957 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 7443517 | 0.002 |
29 | 22634991 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 6778957 | 8 |
0.004 | 4944996 | 5 |
0.005 | 2000000 | 1 |
0.007 | 2500000 | 2 |
0.008 | 1000001 | 1 |
Last trade - 15.52pm 18/10/2024 (20 minute delay) ? |
Featured News
CT1 (ASX) Chart |